{"title":"Natural polysaccharide-engineered POP@ZIF-67 nanoparticles coordinate antibacterial activity, macrophage polarization, and osteogenesis for chronic osteomyelitis therapy.","authors":"Yunchang Zhao, Guangting Zhu, Mengxue Zhang, Yize Wu, Junwei Su, Jing Hu, Chao Jian, Ying Yuan","doi":"10.3389/fbioe.2026.1935416","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic osteomyelitis is difficult to treat due to the interplay of bacterial colonization, excessive inflammation, and impaired bone regeneration. Here, we developed an engineered natural polysaccharide POP@ZIF-67 nanoplatform to modulate these interrelated pathological processes. ZIF-67 is an antimicrobial framework with porous properties, peroxidase-like catalytic activity, and acid-responsive release behavior; purslane polysaccharide (POP) was incorporated as an immunomodulatory component to mitigate the excessive inflammatory stimulation induced by ZIF-67. POP@ZIF-67 exhibits effective antibacterial and antibiofilm activity against <i>Staphylococcus aureus</i>; more importantly, the incorporation of POP transforms the biological action of ZIF-67 from primarily antibacterial stimulation into a multifunctional platform capable of suppressing excessive M1-like macrophage responses, promoting repair-related polarization, and improving the osteogenic microenvironment. In a mouse model of chronic osteomyelitis, POP@ZIF-67 reduced local bacterial load and inflammatory damage while promoting collagen deposition, bone remodeling, and osteogenic maturation, without significant systemic toxicity. Overall, the study introduces an \"antimicrobial framework-immune buffering\" strategy that reconciles the antimicrobial efficacy of metal-organic frameworks with their immunostimulatory limitations. By integrating various therapeutic approaches, POP@ZIF-67 provides a promising new synthetic paradigm for the treatment of chronic osteomyelitis and infectious bone defects.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"14 ","pages":"1935416"},"PeriodicalIF":5.8000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683671/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2026.1935416","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic osteomyelitis is difficult to treat due to the interplay of bacterial colonization, excessive inflammation, and impaired bone regeneration. Here, we developed an engineered natural polysaccharide POP@ZIF-67 nanoplatform to modulate these interrelated pathological processes. ZIF-67 is an antimicrobial framework with porous properties, peroxidase-like catalytic activity, and acid-responsive release behavior; purslane polysaccharide (POP) was incorporated as an immunomodulatory component to mitigate the excessive inflammatory stimulation induced by ZIF-67. POP@ZIF-67 exhibits effective antibacterial and antibiofilm activity against Staphylococcus aureus; more importantly, the incorporation of POP transforms the biological action of ZIF-67 from primarily antibacterial stimulation into a multifunctional platform capable of suppressing excessive M1-like macrophage responses, promoting repair-related polarization, and improving the osteogenic microenvironment. In a mouse model of chronic osteomyelitis, POP@ZIF-67 reduced local bacterial load and inflammatory damage while promoting collagen deposition, bone remodeling, and osteogenic maturation, without significant systemic toxicity. Overall, the study introduces an "antimicrobial framework-immune buffering" strategy that reconciles the antimicrobial efficacy of metal-organic frameworks with their immunostimulatory limitations. By integrating various therapeutic approaches, POP@ZIF-67 provides a promising new synthetic paradigm for the treatment of chronic osteomyelitis and infectious bone defects.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.